Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Jw Cayman Therapeutics Co Ltd
JWCTFJW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China. Address: Building B, Shanghai, China
Analytics
Objectif de Cours de WallStreet
23.17 HKDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés JWCTF
Analyse des dividendes JWCTF
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes JWCTF
Valorisation des titres JWCTF
financières JWCTF
Résultats | 2019 | Dynamique |